Premium
Regulation of matrix metalloproteinases 2 and 9 in corneal neovascularization
Author(s) -
Zhang Jiahao,
Wang Shurong,
He Yuxi,
Yao Boyuan,
Zhang Yan
Publication year - 2020
Publication title -
chemical biology and drug design
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.59
H-Index - 77
eISSN - 1747-0285
pISSN - 1747-0277
DOI - 10.1111/cbdd.13529
Subject(s) - matrix metalloproteinase , angiogenesis , neovascularization , corneal neovascularization , vascular endothelial growth factor , cornea , matrix (chemical analysis) , matrix metalloproteinase inhibitor , choroidal neovascularization , fibroblast growth factor , medicine , microbiology and biotechnology , cancer research , neuroscience , immunology , biology , vegf receptors , chemistry , ophthalmology , macular degeneration , receptor , chromatography
Corneal neovascularization ( CNV ), a pathological process of angiogenesis, can lead to serious consequences in the cornea. CNV is generally proved to associate with inflammation in the cornea closely, which is mainly elicited by the disruption of equilibrium between angiogenic and antiangiogenic factors. Angiogenic factors including vascular endothelial growth factors ( VEGF s), basic fibroblast growth factors ( bFGF s), and matrix metalloproteinases ( MMP s) are vital factors in the formation of CNV . Especially VEGF s are convinced to be the core angiogenic factors in CNV , and MMP s are proved to exert dual effects on the process. Strikingly, matrix metalloproteinase 2 ( MMP ‐2) and matrix metalloproteinase 9 ( MMP ‐9) are determined to play key roles in the formation of CNV , while the mechanism is still vague. In this review, the latest researches are reviewed to discuss the role of MMP ‐2 and MMP ‐9 in CNV , respectively, and some inhibitors of them are presented. We hope to provide a new direction of drug research for CNV .